PARP INHIBITOR
Clinical trials for PARP INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PARP INHIBITOR trials appear
Sign up with your email to follow new studies for PARP INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to outsmart Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs—vismodegib and atezolizumab—in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combination is safe and can shrink tumor…
Matched conditions: PARP INHIBITOR
Phase: PHASE2 • Sponsor: Ronald Buckanovich • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug shows promise for Hard-to-Treat tumors and brain spread
Disease control Recruiting nowThis study tests a new drug called SPR1020 in adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells with specific genetic changes (BRCA or HRR mutations) and may also reach brain tumors. The goal is to find a…
Matched conditions: PARP INHIBITOR
Phase: PHASE1, PHASE2 • Sponsor: Shanghai SciBrunch Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New telehealth program aims to ease fatigue in ovarian cancer patients
Symptom relief Recruiting nowThis study tests a telehealth program called REVITALIZE to see if it can reduce how much fatigue interferes with daily life for adults with advanced ovarian cancer who are taking PARP inhibitors. About 240 participants will either receive the REVITALIZE program or educational mat…
Matched conditions: PARP INHIBITOR
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC